Heart Failure Clinical Trial
— DAPA-MEMRIOfficial title:
An Observational Cross-sectional Study and a Double-blind Placebo Controlled Randomised Controlled Trial to Assess the Effect of Dapagliflozin on Myocardial Calcium-handling in Patients With Heart Failure- The DAPA-MEMRI Trial.
NCT number | NCT04591639 |
Other study ID # | AC20006 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | August 19, 2020 |
Est. completion date | July 28, 2028 |
Diabetes mellitus is among the top 10 causes of death worldwide with an increasing incidence. Patients with diabetes are at risk of developing heart failure which is characterised by significant changes in the heart muscle including scarring and thickening. Contraction of the heart involves movement of calcium across the heart muscle and disruption of this process is an early change seen in heart failure. Recently, a drug therapy (SGLT2 inhibitor therapy) in patients with diabetes was shown to benefit patients with heart failure but the mechanisms of benefit are unknown. Our hypothesis is that calcium handling is altered in patients with either type 2 diabetes mellitus (T2DM) or heart failure and that SGLT2 inhibitors can improve this in heart failure irrespective of the presence of T2DM. Scanning the heart using magnetic resonance imaging (MRI) enables detailed assessment of its structure and function by using a new contrast 'dye' containing manganese that has shown advantages over traditional contrast. We plan to further test this new dye as it has the potential to track and quantify improvements in heart function over time and detect changes in calcium handling in the heart muscle, making it an ideal measure to identify the mechanisms of benefit from SGLT2 inhibitor therapy. The study population will comprise patients with heart failure with and without type 2 diabetes, patients with type 2 diabetes without heart failure and healthy volunteers. Baseline comparisons will be made between the four groups before progressing to the randomised controlled trial with heart failure patients only. Patients will have a clinical assessment and blood tests, electrocardiogram, echocardiogram and MRI of the heart at each visit. If successful, this study will give us significant insights into mechanisms of action of SGLT2 inhibitors in heart failure and will enable us to tailor specific treatments in heart failure patients.
Status | Recruiting |
Enrollment | 160 |
Est. completion date | July 28, 2028 |
Est. primary completion date | July 28, 2028 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Patients with heart failure (with or without type 2 diabetes mellitus) - Aged over 18 years - Diagnosis of symptomatic reduced ejection fraction heart failure for at least 2 months - Left ventricular ejection fraction =40% - Elevated N-terminal pro B-type natriuretic peptide (>125 pg/mL) - Clinical diagnosis of type 2 diabetes mellitus for 50% of patient population - on stable therapy for at least 12 months or more. Patients with Type 2 Diabetes Mellitus and no heart failure - Aged over 18 years - Clinical diagnosis of type 2 diabetes mellitus (diagnosed by either HbA1c of 48mmol/mol (6.5%) or greater or fasting plasma glucose level of 7mmol/L or greater at the time of diagnosis) - on stable therapy for at least 12 months or more. - Normal left ventricular systolic ejection fraction Healthy Volunteers - Aged over 18 years - Normal left ventricular ejection fraction and glycaemia - No clinically significant co-morbid conditions Exclusion Criteria: Patients with heart failure (with or without type 2 diabetes mellitus) - Receiving an SGLT2 inhibitor within 8 weeks of enrolment - Previous intolerance of, or contraindication to, an SGLT2 inhibitor - Standard magnetic resonance imaging safety exclusions - Severe renal impairment (eGFR <30millilitre/min. 1.73m2) - Type 1 diabetes mellitus - Symptomatic hypotension or systolic blood pressure <95 mmHg - Recent (within 12 weeks) hospitalisation for heart failure, acute cardiovascular event (such as myocardial infarction or stroke) or coronary re-vascularisation. - 2nd or 3rd degree atrioventricular block Atrial fibrillation or flutter with poor ventricular rate control (>100 /min) - Heart failure due to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, hypertrophic (obstructive) cardiomyopathy or uncorrected primary valvular disease - New York Heart Association grade IV heart failure - Obstructive liver function testing abnormalities - Concomitant digoxin, diltiazem or verapamil therapy. Patients with type 2 diabetes mellitus and no heart failure - Other major clinically significant co-morbid conditions - History of ischaemic heart disease or present history suggestive of probable clinically significant underlying ischaemic heart disease - Standard magnetic resonance imaging safety exclusions - Moderate or severe renal impairment (eGFR <45 mL/min. 1.73m2) - Receiving a SGLT2 inhibitor at any time - Symptomatic hypotension or systolic blood pressure <95 mmHg - Abnormal electrocardiogram - Clinically significant abnormalities of clinical haematology or biochemistry measurements. Healthy Volunteers - Major or clinically significant cardiovascular disease - Diabetes mellitus - Receiving an SGLT2 inhibitor at any time - Standard magnetic resonance imaging safety exclusions - Moderate or severe renal impairment (eGFR <45 mL/min. 1.73m2) - Symptomatic hypotension or systolic blood pressure <95 mmHg - Abnormal electrocardiogram - Clinically significant abnormalities of clinical haematology or biochemistry measurements. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | University of Edinburgh | Edinburgh | Scotland |
Lead Sponsor | Collaborator |
---|---|
University of Edinburgh | AstraZeneca, NHS Lothian |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of change in myocardial T1 values with manganese enhanced cardiac MRI | 6 months | ||
Secondary | Left ventricular ejection fraction measured in percentage on cardiac MRI | 6 months | ||
Secondary | Left ventricular mass measured in grams on cardiac MRI | 6 months | ||
Secondary | Cardiac biomarkers like N-terminal pro B-type natriuretic peptide in nanogram per litre | 6 months | ||
Secondary | Markers of diabetes control including glucose in millimoles per litre | 6 months | ||
Secondary | Clinical measures such as heart rate in beats per minute | 6 months | ||
Secondary | Extracellular volume in percentage as per cardiac MRI measurements | 6 months | ||
Secondary | Global longitudinal strain in percentage as calculated on cardiac MRI | 6 months | ||
Secondary | Clinical measures such as body weight in Kilograms | 6 months | ||
Secondary | Clinical measures such as blood pressure in millimetres of mercury | 6 months | ||
Secondary | Cardiac biomarkers like high sensitivity cardiac troponin I in nanogram per litre | 6 months | ||
Secondary | Measures of glucose control like glycated haemoglobin (HbA1c) in millimoles per mole | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|